Literature DB >> 3607778

Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.

B J Hazelton, J A Houghton, D M Parham, E C Douglass, P M Torrance, H Holt, P J Houghton.   

Abstract

Three human rhabdomyosarcoma cell lines (Rh10, Rh18, and Rh28) have been established from three independently derived xenografts. These lines have been characterized as mesenchymal in origin (reactivity to desmin and vimentin antibodies) and as expressing a human fetal muscle surface antigen recognized by monoclonal antibody 5.1 H11. Measurable levels of creatine phosphokinase have been detected in the cell lines. Rh10 and Rh28 exhibit the same chromosomal translocation and express an atypical lactate dehydrogenase isoenzyme which may be homologous to those previously reported in other tumor types. The karyotype analysis has confirmed that each cell line was derived from its respective tumor and thus provides a unique model for future investigations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3607778

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

3.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

4.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

5.  PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

Authors:  Wendy Roeb; Antonia Boyer; Webster K Cavenee; Karen C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

6.  Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.

Authors:  Monika Wierdl; Lyudmila Tsurkan; Liying Chi; M Jason Hatfield; Viktor Tollemar; Cori Bradley; Xiang Chen; Chunxu Qu; Philip M Potter
Journal:  Cancer Chemother Pharmacol       Date:  2018-05-31       Impact factor: 3.333

7.  Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.

Authors:  U G Bhat; P Raychaudhuri; W T Beck
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

8.  Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Aditi S Iyengar; Jacob M Loupe; Andrew D Hollenbach
Journal:  Int J Biochem Cell Biol       Date:  2011-03-31       Impact factor: 5.085

9.  In vitro differentiation and proliferation in a newly established human rhabdomyosarcoma cell line.

Authors:  A Ogose; T Motoyama; T Hotta; H Watanabe
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Andrew D Hollenbach
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.